These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8742552)

  • 1. Target populations and interventions in prevention research: what is high risk?
    Pentz MA
    NIDA Res Monogr; 1994; 139():75-93. PubMed ID: 8742552
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug prevention research with Hispanic populations: theoretical and methodological issues and a generic structural model.
    Castro FG; Harmon MP; Coe K; Tafoya-Barraza HM
    NIDA Res Monogr; 1994; 139():203-33. PubMed ID: 8742558
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypothesis formulation and testing in substance use prevention research.
    Hansen WB
    NIDA Res Monogr; 1994; 139():59-74. PubMed ID: 8742551
    [No Abstract]   [Full Text] [Related]  

  • 4. Substance abuse prevention intervention research with Hispanic populations.
    Castro FG; Barrera M; Pantin H; Martinez C; Felix-Ortiz M; Rios R; Lopez VA; Lopez C
    Drug Alcohol Depend; 2006 Sep; 84 Suppl 1():S29-42. PubMed ID: 16787713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some design, measurement, and analysis pitfalls in drug abuse prevention research and how to avoid them: let your model be your guide.
    Collins LM
    NIDA Res Monogr; 1994; 139():95-114. PubMed ID: 8742553
    [No Abstract]   [Full Text] [Related]  

  • 6. A framework for drug abuse prevention research.
    Bukoski WJ
    NIDA Res Monogr; 1991; 107():7-28. PubMed ID: 1922313
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention intervention research: focus and perspective.
    Cázares A
    NIDA Res Monogr; 1994; 139():5-35. PubMed ID: 8742549
    [No Abstract]   [Full Text] [Related]  

  • 8. Gathering epidemiologic information on inhalant abuse: some methodological issues.
    Frank B
    NIDA Res Monogr; 1995; 148():260-73. PubMed ID: 8929894
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug addiction in adolescence].
    Carrot-Courtillot C
    Soins Pediatr Pueric; 1999; (191):4-9. PubMed ID: 10857425
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study.
    de Graaf R; Bijl RV; Ten Have M; Beekman AT; Vollebergh WA
    J Affect Disord; 2004 Nov; 82(3):461-7. PubMed ID: 15555699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug prevention research with Native-American populations: some considerations.
    Powless Sage G
    NIDA Res Monogr; 1994; 139():235-48. PubMed ID: 8742559
    [No Abstract]   [Full Text] [Related]  

  • 12. Errors in assessing DSM-IV substance use disorders.
    Grant BF; Compton WM; Crowley TJ; Hasin DS; Helzer JE; Li TK; Rounsaville BJ; Volkow ND; Woody GE
    Arch Gen Psychiatry; 2007 Mar; 64(3):379-80; author reply 381-2. PubMed ID: 17339528
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhancing the validity and utility of randomized clinical trials in addictions treatment research: II. Participant samples and assessment.
    Del Boca FK; Darkes J
    Addiction; 2007 Aug; 102(8):1194-203. PubMed ID: 17511752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction for the design effect in school-based substance use and abuse prevention research: sample size requirements and analysis considerations.
    Dielman TE
    NIDA Res Monogr; 1994; 139():115-25. PubMed ID: 8742554
    [No Abstract]   [Full Text] [Related]  

  • 15. Childhood stimulant treatment and risk for later substance abuse.
    Fischer M; Barkley RA
    J Clin Psychiatry; 2003; 64 Suppl 11():19-23. PubMed ID: 14529326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New statistical methods for substance use prevention research.
    Collins LM; Seitz LA
    NIDA Res Monogr; 1994; 142():1-12. PubMed ID: 9243531
    [No Abstract]   [Full Text] [Related]  

  • 17. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A province-based surveillance system for the risk factors of non-communicable diseases: A prototype for integration of risk factor surveillance into primary healthcare systems of developing countries.
    Alikhani S; Delavari A; Alaedini F; Kelishadi R; Rohbani S; Safaei A
    Public Health; 2009 May; 123(5):358-64. PubMed ID: 19386334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental and quasi-experimental designs in prevention research.
    Snow DL; Tebes JK
    NIDA Res Monogr; 1991; 107():140-58. PubMed ID: 1922303
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV risk behavioral surveillance: a methodology for monitoring behavioral trends.
    Mills S; Saidel T; Bennett A; Rehle T; Hogle J; Brown T; Magnani R
    AIDS; 1998; 12 Suppl 2():S37-46. PubMed ID: 9792360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.